Biologics CDMO Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Biologics CDMO Market Report is Segmented by Type (Mammalian and Non-Mammalian (Microbial)), Product Type (Biologics (Monoclonal, Recombinant Proteins, Antisense and Molecular Therapy, Vaccines, and Other Biologics) and Biosimilars), and Geography (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa). The Market Sizes and Forecasts are Provided in Terms of Value (USD) for all the Above Segments.

Biologics CDMO Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Biologics Contract Development & Manufacturing Organization (CDMO) Market Size

Biologics CDMO Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 20.15 Billion
Market Size (2030) USD 33.75 Billion
CAGR (2025 - 2030) 10.87 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Low

Major Players

Biologics CDMO Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Biologics CDMO Market with other markets in Packaging Industry

Advanced Packaging

Packaging Equipment

Contract Packaging

Overall Packaging

Packaging Customers

Packaging Forms

Biologics Contract Development and Manufacturing Organization (CDMO) Market Analysis

The Biologics CDMO Market size is estimated at USD 20.15 billion in 2025, and is expected to reach USD 33.75 billion by 2030, at a CAGR of 10.87% during the forecast period (2025-2030).

The global pharmaceutical industry is growing exponentially, driven by global economic growth, a growing and aging population, and new product launches. Even though small molecules continue to command the prominent share of the market, large molecules, such as biologics, biosimilars, and cell and gene therapies, are expected to witness the fastest growth over the forecast period.

  • Cancer therapies are among the primary drivers for a large proportion of the growth in the biologics market. Even with the faster growth forecast, small molecules outweigh biologics in terms of drug approvals. For instance, the FDA's Center for Drug Evaluation and Research (CDER) approved many new drugs and biological products in recent years.
  • The advancements in tag technology and blockchain are mainly helping pharmaceutical companies with serialization requirements. Although blockchain technology cannot be used in the pharmaceutical industry to label actual drug products, digital ledger technology is significantly being implemented as a two-dimensional barcoding system. The technology is then utilized to authenticate containers throughout the supply chain.
  • Cost-of-goods for a biological API are far higher than those for a drug product because of the technically challenging and capital-intensive API development and manufacturing process. About three-quarters of the revenue from biologics and outsourcing comes from API production, and CDMOs invest heavily to expand capacity. Biologic drugs are high-value, high-margin products, so pharma companies are mainly focused on supply security rather than investing in manufacturing.
  • Capacity constraints are still a problem in the pharmaceutical industry, and almost 6 in 10 pharma manufacturers face minor constraints at some manufacturing stage. In the current market scenario, capacity utilization information is essential for planners and investors to determine whether capacity will be available to produce pipeline drugs nearing approval. While most breakthroughs in the future are expected from bio-pharma, mass production capacity constraint is driving costs.
  • The COVID-19 outbreak drives health costs and further strains federal and state government finances. It's possible that many Americans lost their employer-based private health plans due to job loss or sickness. The United States spends more on health care than any other country. For instance, the Centers for Medicare & Medicaid Services has predicted the total national health spending in the United States from 2021 to 2030. The United States is expected to spend USD 6.7 trillion on healthcare by 2030.

Biologics Contract Development & Manufacturing Organization (CDMO) Industry Overview

The biologics contract development and manufacturing organization (CDMO) market is highly fragmented due to the presence of both global players and small and medium-sized enterprises. Some of the major players in the market are Boehringer Ingelheim Group, Wuxi Biologics (Cayman) Inc., Samsung Biologics, Lonza Group Ltd, and Fujifilm Diosynth Biotechnologies USA Inc. Players in the market are adopting strategies such as partnerships and acquisitions to enhance their product offerings and gain sustainable competitive advantage.

In March 2024, WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that it had broken ground on its 13.5-hectare CRDMO center in Tuas Biomedical Park in Singapore. The center will provide integrated biologics research and development along with manufacturing services. The CRDMO site also includes an additional 120,000L manufacturing capacity to WuXi Biologics’ global network.

In January 2024, Boehringer Ingelheim, the research-driven biopharmaceutical company, announced an expansion and upgrade of its plant in Koropi, Greece. The company announced an increase in the manufacturing capacity of new and existing medications that are in late-stage development, with an investment of EUR 120 million (USD 129.99 million).

Biologics Contract Development & Manufacturing Organization (CDMO) Market Leaders

  1. Boehringer Ingelheim Group

  2. Wuxi Biologics (Cayman) Inc.

  3. Samsung Biologics

  4. Lonza Group Ltd

  5. Fujifilm Diosynth Biotechnologies USA Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Biologics Contract Development & Manufacturing Organization (CDMO) Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Biologics Contract Development & Manufacturing Organization (CDMO) Market News

  • In March 2024, FUJIFILM Diosynth Biotechnologies announced an expansion of its manufacturing agreement with Argenx to provide drug products and services for efgartigimod, a monoclonal antibody (mAb) fragment to target the neonatal Fc receptor (FcRn), in patients with severe autoimmune disease.
  • In February 2024, Samsung Biologics partnered with LegoChem Biosciences, a biotech company, to research and develop antibody-drug conjugate (ADC) programs. As part of the partnership, Samsung Biologics will provide antibody development and drug substance manufacturing services to treat solid tumors as a part of LegoChem Biosciences’ ADC program.

Biologics CDMO Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Access to New Technologies and Higher Speed of Execution Realized By CDMOs
    • 4.2.2 Need for High Capital Investments to Develop Capabilities Led to the Demand for the Outsourcing Model
    • 4.2.3 Lack of In-house Capacity among Emerging Drug Development Companies
  • 4.3 Market Challenges/ Restraints
    • 4.3.1 Transfer Complexities and Concerns over the Breach of IP and Patents
    • 4.3.2 Capacity Issues Related to Large-molecule Drugs
  • 4.4 Market Opportunities (Emergence of the Concept of Biosimilars Co-development and Designer Cell Lines)
  • 4.5 Key Considerations Involved in the Selection of Biologics CDMO Vendors
  • 4.6 Business Model Analysis - Value Added, Flexible Capacity Risk Sharing, and In-time Manufacturing
  • 4.7 Key Trends in Biopharmaceutical Industry
  • 4.8 Coverage on the Current Use of Biologics for Different Types of Disease Treatment

5. MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Mammalian
    • 5.1.2 Non-mammalian (Microbial)
  • 5.2 By Product Type
    • 5.2.1 Biologics
    • 5.2.1.1 Monoclonal (Diagnostic, Therapeutic, and Protein-based)
    • 5.2.1.2 Recombinant Proteins
    • 5.2.1.3 Antisense and Molecular Therapy
    • 5.2.1.4 Vaccines
    • 5.2.1.5 Other Biologics
    • 5.2.2 Biosimilars
  • 5.3 By Geography***
    • 5.3.1 North America
    • 5.3.2 Europe
    • 5.3.3 Asia
    • 5.3.4 Australia and New Zealand
    • 5.3.5 Latin America
    • 5.3.6 Middle East and Africa

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles*
    • 6.1.1 Boehringer Ingelheim Group
    • 6.1.2 Wuxi Biologics (Cayman) Inc.
    • 6.1.3 Samsung Biologics
    • 6.1.4 Lonza Group Ltd
    • 6.1.5 Fujifilm Diosynth Biotechnologies USA Inc.
    • 6.1.6 Toyobo Co. Ltd
    • 6.1.7 Parexel International Corp.
    • 6.1.8 Icon PLC
    • 6.1.9 Binex Co. Ltd
    • 6.1.10 Celonic Group (JRS Pharma Group)
    • 6.1.11 Rentschler Biopharma SE
    • 6.1.12 AGC Biologics (AGC Inc.)
    • 6.1.13 Sandoz AG
    • 6.1.14 Catalent Inc.
    • 6.1.15 AbbVie Inc.

7. VENDOR MARKET SHARE

8. INVESTMENT ANALYSIS

9. FUTURE OUTLOOK OF THE MARKET

**Subject to Availability
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Biologics Contract Development & Manufacturing Organization (CDMO) Industry Segmentation

The biologics contract development and manufacturing organization (CDMO) market is segmented by type (Mammalian and Non-Mammalian (Microbial)), by product type (biologics [monoclonal, recombinant proteins, antisense, and molecular therapy, vaccines, and other biologics], and biosimilars), by geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The market sizes and forecasts are provided in terms of value in USD for all the above segments.

By Type Mammalian
Non-mammalian (Microbial)
By Product Type Biologics Monoclonal (Diagnostic, Therapeutic, and Protein-based)
Recombinant Proteins
Antisense and Molecular Therapy
Vaccines
Other Biologics
Biosimilars
By Geography*** North America
Europe
Asia
Australia and New Zealand
Latin America
Middle East and Africa
Need A Different Region or Segment?
Customize Now

Biologics CDMO Market Research Faqs

How big is the Biologics CDMO Market?

The Biologics CDMO Market size is expected to reach USD 20.15 billion in 2025 and grow at a CAGR of 10.87% to reach USD 33.75 billion by 2030.

What is the current Biologics CDMO Market size?

In 2025, the Biologics CDMO Market size is expected to reach USD 20.15 billion.

Who are the key players in Biologics CDMO Market?

Boehringer Ingelheim Group, Wuxi Biologics (Cayman) Inc., Samsung Biologics, Lonza Group Ltd and Fujifilm Diosynth Biotechnologies USA Inc. are the major companies operating in the Biologics CDMO Market.

Which is the fastest growing region in Biologics CDMO Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Biologics CDMO Market?

In 2025, the North America accounts for the largest market share in Biologics CDMO Market.

What years does this Biologics CDMO Market cover, and what was the market size in 2024?

In 2024, the Biologics CDMO Market size was estimated at USD 17.96 billion. The report covers the Biologics CDMO Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Biologics CDMO Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Biologics CDMO Industry Report

The Biologics CDMO Market Report is segmented by type, product type, and geography. The market size is expanding, driven by the growing demand for outsourcing services in the biopharmaceutical industry. This market overview highlights the significance of biologics CDMOs, which offer specialized expertise, advanced technologies, and cost-effective solutions essential for developing and manufacturing biologic drugs. The industry analysis indicates that companies are increasingly relying on CDMOs for their comprehensive solutions, thereby enhancing the capacity, flexibility, and efficiency of drug development processes.

The market growth is supported by the rising demand for biologics such as monoclonal antibodies, recombinant proteins, and gene therapies. The industry trends show a diverse range of CDMOs catering to different segments of the biopharmaceutical landscape. This market forecast suggests that the global market for biologics CDMOs will continue to expand, driven by the need for innovative biologics. The market segmentation includes detailed statistics on market share, size, and revenue growth rate, providing a comprehensive market analysis.

The industry outlook is positive, with market leaders offering solutions across the development and manufacturing spectrum. The market value is expected to increase as the demand for biologics grows. The market predictions and market review indicate a strong future for the biologics CDMO market. The industry reports available from Mordor Intelligence™ provide detailed market data, including historical overviews and future forecasts.

For those interested in further details, the report pdf is available for download, offering a deeper dive into the market research. This report example serves as a valuable resource for understanding the dynamics of the biologics CDMO market, including industry sales, industry size, and industry statistics. Research companies and industry researchers will find this report particularly useful for gaining insights into the market outlook and market trends.